Herbal composition for treating metastatic breast cancer

Abstract

The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention relates to a herbal composition for treating metastatic breast cancer.[0003]2. Description of Prior Art[0004]Breast cancer, a leading cause of morbidity and mortality among women, was estimated to account for 23% (1.38 million) of new cancer cases and 14% (458,400) of cancer deaths worldwide in 2008. In Taiwan, breast cancer was the most common cancer among women, with an incidence of 9,049 cases per 100,000 population, and the fourth leading cause of cancer-related deaths in 2008. Despite advances in the treatment of breast cancer, it is estimated that 30-50% of women initially diagnosed with earlier stages of breast cancer eventually develop metastatic disease. Unfortunately, breast cancer has a poor prognosis following metastasis, and women with metastatic breast cancer have a limited survival of 18-24 months, and a 5-year survival rate of approximately 20%. The progression to metastatic disease...

AI Technical Summary

Benefits of technology

This patent is about a composition made from several herbs, including Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. This composition is effective in treating metastatic breast cancer in humans. The technical effect of this invention is a more effective treatment for metastatic breast cancer.

Problems solved by technology

Unfortunately, breast cancer has a poor prognosis following metastasis, and women with metastatic breast cancer have a limited survival of 18-24 months, and a 5-year survival rate of approximately 20%.

The progression to metastatic disease is further exacerbated by the increasing use of chemotherapy in early-stage breast cancer, which has led to a corresponding increase in the number of metastatic breast cancer cases refractory to conventional treatments.

However, there is no global consensus and guidelines for the treatment of metastatic breast cancer, and treatment is highly individualized and varies worldwide.

Furthermore, due to the poor prognosis of metastatic breast cancer, the main goals of treatment are palliative rather than curative.

However, the significant side effects, potential for the development of treatment resistance, and limited survival benefit associated with conventional treatments has prompted the use of complementary and alternative medicine (CAM) in patients with advanced malignancies.

Images